ArticleProceedings of the National Academy of Sciences of the United States of America2020
Dual self-regulated delivery of insulin and glucagon by a hybrid patch.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 111 citations in OpenAlex.
- Next-generation microneedle patches for transdermal therapeutics and diagnostics.Discover nano · 2026Review
- Review
- Epigallocatechin gallate prevents and alleviates type 2 diabetes mellitus (T2DM) through gut microbiota and multi-organ interactions in Wistar healthy rats and GK T2DM rats.Journal of advanced research · 2026Article
- [Advances in injectable and transdermal glucose-responsive insulin delivery systems].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- A flexible wireless skin patch for synchronized glucose monitoring and regulation.Microsystems & nanoengineering · 2026Article
- Material-driven glucose responsiveness in insulin delivery systems: carrier selection and performance.Frontiers in endocrinology · 2026Review
- A Computational Glucoregulatory Model of Liver and Glucagon for the Evaluation of Therapeutics.ACS pharmacology & translational science · 2025Article
- Ultrastable Insulin-Glucagon Fusion Protein Exploits an Endogenous Hepatic Switch to Mitigate Hypoglycemic Risk.ACS pharmacology & translational science · 2025Article
- Event-triggered smart dual hormone artificial pancreas for patient-specific drug delivery.Scientific reports · 2025Article
- Microenvironment-feedback regulated hydrogels as living wound healing materials.Nature communications · 2025Article
- Catechol-based chemistry for hypoglycemia-responsive delivery of zinc-glucagon via hydrogel-based microneedle patch technology.Nature communications · 2025Article
- Glucose-Responsive Materials for Smart Insulin Delivery: From Protein-Based to Protein-Free Design.ACS materials Au · 2025Review
- Inducing In Situ MBiomaterials research · 2025Article
- Strategies for transportation of peptides across the skin for treatment of multiple diseases.Therapeutic delivery · 2025Review
- A Glucose-Responsive Glucagon-Micelle for the Prevention of Hypoglycemia.ACS central science · 2024Article
- Analysis of Glucose Responsive Glucagon Therapeutics using Computational Models of the Glucoregulatory System.Advanced healthcare materials · 2024Article
- Microneedle-assisted dual delivery of PUMA gene and celastrol for synergistic therapy of rheumatoid arthritis through restoring synovial homeostasis.Bioactive materials · 2024Article
- Highly stretchable and customizable microneedle electrode arrays for intramuscular electromyography.Science advances · 2024Article
- Article
- Glucose-Triggered Gelation of Supramolecular Peptide Nanocoils with Glucose-Binding Motifs.Advanced materials (Deerfield Beach, Fla.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Reduced β-cell function and insulin deficiency are hallmarks of diabetes mellitus, which is often accompanied by the malfunction of glucagon-secreting α-cells. While insulin therapy has been developed to treat insulin deficiency, the on-demand supplementation of glucagon for acute hypoglycemia treatment remains inadequate. Here, we describe a transdermal patch that mimics the inherent counterregulatory effects of β-cells and α-cells for blood glucose management by dynamically releasing insulin or glucagon. The two modules share a copolymerized matrix but comprise different ratios of the key monomers to be "dually responsive" to both hyper- and hypoglycemic conditions. In a type 1 diabetic mouse model, the hybrid patch effectively controls hyperglycemia while minimizing the occurrence of hypoglycemia in the setting of insulin therapy with simulated delayed meal or insulin overdose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.